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Abstract
TRPC channels are a family of nonselective cation channels that regulate ion homeostasis and intracellular Ca
2+ signaling in
numerous cell types. Important physiological functions such as vasoregulation, neuronal growth, and pheromone
recognition have been assigned to this class of ion channels. Despite their physiological relevance, few selective
pharmacological tools are available to study TRPC channel function. We, therefore, screened a selection of
pharmacologically active compounds for TRPC modulating activity. We found that the synthetic gestagen norgestimate
inhibited diacylglycerol-sensitive TRPC3 and TRPC6 with IC50s of 3–5 mM, while half-maximal inhibition of TRPC5 required
significantly higher compound concentrations (.10 mM). Norgestimate blocked TRPC-mediated vasopressin-induced cation
currents in A7r5 smooth muscle cells and caused vasorelaxation of isolated rat aorta, indicating that norgestimate could be
an interesting tool for the investigation of TRP channel function in native cells and tissues. The steroid hormone
progesterone, which is structurally related to norgestimate, also inhibited TRPC channel activity with IC50s ranging from 6 to
18 mM but showed little subtype selectivity. Thus, TRPC channel inhibition by high gestational levels of progesterone may
contribute to the physiological decrease of uterine contractility and immunosuppression during pregnancy.
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Introduction
Transient receptor potential canonical (TRPC) channels belong
to the TRP cation channel superfamily. Seven TRPC channels,
TRPC1–7, have been found in rodents. They all conduct Ca
2+ in
addition to monovalent cations and can be activated via
membrane receptors linked to phospholipase C signaling.
Downstream of phospholipase C the activation mechanisms of
TRPC channels are not well defined but one subclass, namely
TRPC3, 26 and 27, as well as the structurally more distinct
TRPC2 respond to the phospholipase C hydrolysis product
diacylglycerol. The remaining family members, however, are
diacylglycerol-insensitive (reviewed in [1–3]).
Genetic models have been instrumental in defining the
physiological roles of TRPC channels. The involvement of
TRPC4 and TRPC6 in vasoregulation [4,5], TRPC1 in muscle
function [6,7], TRPC2 in pheromone signaling [8,9], TRPC3 in
motor coordination [10,11], and most recently of TRPC5 [12] in
innate fear responses has been elucidated using knockout mice.
Despite the substantial progress made, important questions
regarding TRPC channel function and regulation remain, and it
would be highly desirable to verify and extent studies in genetically
modified mice by pharmacological means in non-engineered
animals. Unfortunately, such experiments have proved difficult
due to the lack of specific compounds that modulate TRPC
channels. Tools such as SKF96365 [13,14], KB-R7943 [15] or
BTP-2 [16] do not discriminate between TRPC homologs and
also alter the activity of other ion channels or transporters [14,17].
Only recently the first subtype –specific TRPC inhibitor was
discovered. This compound, the pyrazole Pyr3, inhibited TRPC3
with a half maximal inhibitory concentration (IC50) of 0.7 mM
without having effects on other TRPC channels. Using Pyr3 an
involvement of TRPC3 in the development of cardiac hypertro-
phy could be demonstrated in vivo [18].
To enrich the repertoire of pharmacological tool compounds for
TRPC channels and to identify new natural channel modulators,
we screened a library of pharmacologically and biologically active
compounds for their effects on TRPC6-mediated Ca
2+ entry. We
found that norgestimate, a synthetic steroid and active ingredient
of certain contraceptives, preferentially inhibited TRPC3 and 26
channels at low micromolar concentrations. The endogenous
gestagen progesterone also inhibited TRPC channels but showed
little subtype selectivity.
Interestingly, a recent study by Majeed et al. [19] demonstrated
inhibition of TRPC5 by neurosteroids including pregnenolone
sulphate and progesterone. Our data now show that steroid
modulation is a common feature of TRPC family members and
reveal structural determinants of selective TRPC channel
inhibition by progestins.
Hence, TRPC channels may contribute to diverse steroid
actions ranging from progesterone-induced vascular remodelling
and decrease in uterine contractility during pregnancy to
cardiovascular side-effects of oral contraceptives.
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Cell culture and cell line generation
Cells were grown at 37uC in a humidified atmosphere (5% or
7% CO2) under standard cell culture conditions. Stable human
embryonic kidney (HEK) cell lines expressing recombinant
mTRPC4ß (GenBank accession number AAC05178); mTRPC5
(GenBank accession number NM_009428) or hTRPC6 (GenBank
accession number AF080394) under the control of a tetracycline-
inducible promoter were generated using the Flp-In T-Rex (FITR)
system (Invitrogen, Karlsruhe, Germany). TRPC4/5/6 HEK-
FITR cells were maintained in Dulbecco’s modified eagle medium
(DMEM, with glutaMAX I, 4.5 g/l glucose and 110 mg/ml
sodium pyruvate) supplemented with 10% (v/v) fetal bovine serum
(Biochrom, Berlin, Germany), 1 mM glutamine, 1 mM MEM
sodium pyruvate, 40 mg/ml hygromycin (50 mg/ml for mTRPC5
HEK-FITR cells), and 15 mg/ml blasticidine HCl. Channel
expression was induced by supplementing the growth medium
for 18–24 h with 1 mg/ml doxycycline.
hTRPC3 (GenBank accession number NM_003305) was stably
expressed in chinese hamster ovary (CHO) cells using a
proprietary high expression vector (Steinbeis –Transferzentrum
fu ¨r Angewandte Biologische Chemie, Mannheim, Germany).
For measurement of norgestimate effects on adrenoceptor
signaling a CHO cell line stably expressing human a1A-receptors
(GenBank accession number NM_000680.2) under control of a
CMV promoter was used. CHO cells were kept in HAM’s F-12
medium (with glutaMAX I) supplemented with 10% (v/v) fetal
bovine serum (Biochrom), 1 mM glutamine, and 0.6 mg/ml
geneticin.
A7r5 cells (ATCC, Rockville, USA) were maintained in DMEM
(with glutaMAX I, 4.5 g/l glucose and 110 mg/ml sodium
pyruvate), supplemented with 10% (v/v) fetal bovine serum
(PAA, Pasching, Austria).
Measurement of intracellular calcium concentration
([Ca
2+]i)
Fluo-4 measurements. Cells grown to an almost confluent
monolayer on black poly-D-lysine coated 96-well plates (Greiner,
Frickenhausen, Germany) were washed with standard
extracellular solution (140 mM NaCl, 1 mM MgCl2, 5.4 mM
KCl, 2 mM CaCl2, 10 mM HEPES, 10 mM glucose, pH 7.35)
and stained (30 min, room temperature) with dye solution (2 mM
fluo-4 AM, 0.02% pluronic F127, 0.1% bovine serum albumin in
standard extracellular solution). Cells were washed and either
incubated with standard extracellular solution only or with
different concentrations of test compounds for 10 min. Fluo-4
fluorescence was excited at 488 nm with an argon laser and
measured using a fluorometric imaging plate reader (Molecular
Devices, Sunnyvale, USA). All fluorometric measurements were
performed at room temperature.
Ca
2+ entry into TRPC3 CHO and TRPC6 HEK-FITR cells
was elicited by application of the diacylglycerol analog 1-oleoyl-2-
acetyl-sn-glycerol (OAG). For calculation of norgestimate- and
progesterone-induced inhibition of TRPC3- and TRPC6-mediat-
ed Ca
2+ entry fluorescence values were plotted versus time and the
area under the curve was considered as a measure of Ca
2+ influx.
Baseline fluorescence in non-OAG-stimulated cells and OAG-
stimulated Ca
2+ influx into control cells not treated with inhibitors
were defined as 0% and 100% influx, respectively.
TRPC4- and TRPC5-mediated Ca
2+ influx was stimulated by
application of trypsin that activates endogenous Gq-coupled
protease activated receptors in HEK cells [20]. As trypsin, via
phospholipase C activation, causes Ca
2+ release from internal
stores (PI response) and subsequent Ca
2+ entry through native
store-operated channels, these components had to be subtracted
from the total fluorescence signal in order to determine TRPC-
mediated Ca
2+ entry. For this purpose trypsin-induced Ca
2+
responses in non-induced TRPC4- and TRPC5 HEK-FITR cells
lacking functional expression of the TRPC channels were
measured in parallel to responses in induced cells and were
subtracted from the fluorescence traces. Compound effects were
then calculated from the area under the curve and normalized to
the Ca
2+ influx into trypsin-stimulated, non-compound-treated
cells.
[Ca
2+]i measurements in CHO cells stably expressing human
a1A –receptors were performed essentially as described for HEK-
FITR cells. The a1- agonist phenylephrine was used for receptor
stimulation.
Fura-2 measurements. Cells grown on poly-L-lysine-coated
24-mm glass coverslips were loaded in cell culture medium
supplemented with 2 mM fura-2 AM (30 min, 37uC) and
subsequently allowed to de-esterify in standard extracellular
solution (15 min, 37uC). Changes in [Ca
2+]i were measured
using a monochromator-based imaging system (T.I.L.L.
Photonics, Gra ¨felfing, Germany) mounted on an inverted
Axiovert 200 microscope (Zeiss, Go ¨ttingen, Germany).
Fluorescence was excited alternating at 340 nm and 380 nm,
long-pass filtered at 440 nm and captured at 2 s intervals. The
340/380 nm excitation ratio of selected cell areas was calculated
with T.I.L.L. vision 4.0 software (T.I.L.L. Photonics) after
correction for background fluorescence.
Electrophysiological techniques
The whole-cell patch clamp technique [21] was employed to
measure ion currents from single cells. Heat-polished patch
pipettes with resistances of 2–4 MV were pulled from borosilicate
glass capillaries (Hilgenberg, Malsfeld, Germany) using a DMZ-
Universal puller (Zeitz-Instruments, Munich, Germany) and filled
with standard intracellular solution containing: 120 mM CsOH,
120 mM gluconic acid, 2 mM MgCl2, 3 mM CaCl2, 5 mM Cs4-
BAPTA, 10 mM HEPES (pH 7.4 adjusted with gluconic acid).
For agonist-independent stimulation of TRPC currents the
intracellular solution was supplemented with 30 mM AlCl3 and
10 mM NaF and cells were infused with AlF4
2 through the patch
pipette. AlF4
2 is a non-specific activator of heterotrimeric G
proteins that consequently leads to increased phospholipase C
activity and TRPC channel activation.
The extracellular solution for recording of TRPC currents
contained: 140 mM NaCl, 5.4 mM KCl, 2 mM CaCl2,1m M
MgCl2, 10 mM glucose, 10 mM HEPES (pH 7.4 adjusted with
NaOH).
For measurement of [Arg
8]-vasopressin (AVP) – induced
currents in A7r5 cells the Ca
2+ concentration of the extracellular
solution was lowered to 0.2 mM.
Cells grown on poly-L-lysine-coated coverslips were continu-
ously superfused with extracellular solution and substances were
applied using an ALA BPS-8 perfusion system (ALA Scientific
Instruments, Westbury, USA). Whole-cell recordings were per-
formed with an EPC-10 amplifier and Pulse software (HEKA,
Lambrecht, Germany). Cells were held at 270 mV, and current-
voltage (I–V) relationships were routinely measured every 2 or 3 s
by applying voltage ramps (180 ms) from 2100 mV to +80 mV.
Data was acquired at 6.67 kHz and filtered with 2.22 kHz. After
establishing the whole cell configuration the series resistance was
usually ,10 MV and was compensated 50–70%. All experiments
were performed at room temperature.
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Animals were used for organ retrieval only and were sacrificed
according to Sanofi-Aventis Ethical Committee guidelines and to
the Guide for the Care and Use of Laboratory Animals published
by the National Institutes of Health. Sanofi-Aventis is an
authorized institution to house and handle laboratory animals
according 111 German Animal Welfare Act, and has a nominated
animal welfare officer. Sanofi-Aventis is also AAALAC (Associa-
tion for Assessment and Accreditation of Laboratory Animal Care
International) accredited. The competent authority (Regierung-
spra ¨sidium Darmstadt) has been notified of the procedure under
protocol number T04-01/102.
In vitro vascular function
Adult male Wistar-Unilever rats (8–11 weeks old; Harlan
Winkelmann, Borchen, Germany) were sacrificed by decapitation.
Thoracic aortas were excised quickly, transferred to cold (4uC),
carbogen (95% O2 and 5% CO2) bubbled physiological salt
solution (119 mM NaCl, 4.7 mM KCl, 1.2 KH2PO4, 1.2 mM
MgSO4, 1.6 mM CaCl2, 25 mM NaHCO3, 11 mM glucose) and
rinsed. After removal of connective tissue and perivascular fat
aortas were dissected in 5 mm rings, connected to force
transducers and equilibrated in carbogen bubbled physiological
salt solution at 37uC for 15 min. Aortic rings were set at 1000 mg
passive tension and contractile forces were then measured
isometrically using standard bath procedures as described earlier
[22]. Vessels strongly contracting after application of 60 mM KCl
were defined as intact and used for further experiments. To
minimize the contribution of endothelium-derived nitric oxide to
compound-induced force changes experiments were performed in
the presence of the nitric oxide synthase inhibitor nitro-L-arginine
methyl ester (L-NAME).
Materials
DMEM, HAM’s F12, glutamine, MEM sodium pyruvate,
hygromycin B, blasticidine HCl, geneticin, Fura-2 AM, Fluo-4
AM, Pluronic F127, and Cs4-BAPTA were from Invitrogen,
MgCl2 and MgSO4 from Merck (Darmstadt, Germany), doxycy-
cline from BD Biosciences (Heidelberg, Germany), OAG from
Avanti Polar Lipids Inc. (Alabaster, USA), and norgestimate from
ChemPacific Corporation (Baltimore, USA). All other chemicals
were from Sigma-Aldrich (Munich, Germany).
Statistics
For statistical analysis, analysis of variance was performed with
Origin 6.0 software (Microcal Software Inc., Northampton, USA).
Figure 1. Norgestimate inhibits TRPC3- and TRPC6-mediated Ca
2+ influx. OAG-induced changes of [Ca
2+]i in fluo-4-loaded TRPC3 CHO cells
(A) and TRPC6 HEK-FITR cells (C) were measured in 96-well plates using a fluorometric imaging plate reader. Pre-incubation of cells with 30 mM
norgestimate (NG) significantly reduced TRPC3 and 26 mediated Ca
2+ entry. Representative fluorescence traces are shown. Concentration-response
curves for inhibition of TRPC3 (B) and TRPC6 (D) by norgestimate were derived from the area under the fluorescence curves for each given
concentration. The solid lines represent the best fit of the data to the Hill model with slopes of n=1.67 (TRPC3) and n=0.97 (TRPC6). Means 6 SEM of
3 wells (B) or 4 wells (D) are shown. The chemical structure of norgestimate is illustrated in B.
doi:10.1371/journal.pone.0035393.g001
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IC50 were calculated with SigmaPlot (Systat software, San Jose,
USA) using the sigmoidal Hill-model: f=100 (C
n/(IC50
n+C
n));
where f is the inhibition, C is the applied drug concentration and n
is the Hill coefficient. The half maximal effective concentration
(EC50) of norgestimate-induced vasorelaxation was calculated
analogously with R=y0+y1C
n/(EC50
n+C
n); where R is relaxation,
yo and y1 are constants, C is the applied drug concentration and n
is the Hill coefficient. Averaged data is expressed as means 6
SEM.
Results
In order to discover compounds that modulate TRPC activity
we developed fluorescence-based assays that allowed to measure
TRPC-mediated Ca
2+ entry using fluorometric imaging plate
reader technology. Screening a selection of pharmacologically and
biologically active compounds using these assays identified
norgestimate as a potent TRPC3 and 26 channel inhibitor.
Norgestimate blocked OAG-induced Ca
2+-entry in TRPC3 and
TRPC6 expressing cells with similar potency. IC50s amounted to
3.0 and 5.2 mM, respectively (Figure 1).
Figure 2. Potent inhibition of TRPC3- and TRPC6-mediated currents by norgestimate. Effect of 10 mM norgestimate (NG) on whole-cell
currents evoked by AlF4
2 infusion into TRPC3 (A) and TRPC6 (B) expressing cells. Current-voltage (I–V) relationships (left panels) and time course of
currents recorded at 270 mV (right panels) are shown. For measurement of I–V curves voltage ramps from 2100 to +80 mV were applied at the time
points indicated. Background currents were isolated by blocking of TRPC3 and 26 with 100 mML a
3+. Comparison of the mean inhibition of TRPC3
and 26b y1 0mM norgestimate (C) demonstrates equipotent suppression of both channels. N denotes the number of tested cells. Concentration-
response relationship of the inhibition of TRPC6 by norgestimate (D). Means 6 SEM of n$3 experiments per concentration are shown. The line
represents the best fit of the data to the dose-response equation with a Hill slope of 1.19.
doi:10.1371/journal.pone.0035393.g002
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currents we performed patch clamp experiments using the same
TRPC expressing cell lines used for Ca
2+ measurements. These
experiments confirmed that 10 mM norgestimate almost com-
pletely inhibited TRPC3 and 26( Figure 2A–C). Further
evaluation of the dose dependence of TRPC6 current inhibition
by norgestimate yielded an IC50 of 3.06 mM( Figure 2D). Thus,
both direct current measurements and indirect fluorescence
experiments showed a similar inhibitory activity of norgestimate
towards TRPC3 and 26.
Steroid-sensitivity had previously been established for TRPC5
[19] which together with its close homolog TRPC4 defines a
distinct subclass of TRPC channels that is not activated by
diacylglycerol. We wanted to test the subtype selectivity of
norgestimate and, therefore, studied the effect of the compound
on TRPC5.
As illustrated in Figure 3 norgestimate suppressed TRPC5-
mediated currents with an IC50 of 13.6 mM, indicating a
considerably lower potency of the synthetic gestagen towards this
diacylglycerol-insensitive TRPC channel. Unfortunately, we were
unable to determine the effects of norgestimate on TRPC4
currents since compound effects at 10 mM were apparently small,
irreversible and could not be separated from the significant run-
down of TRPC4-mediated currents.
Having established the prominent inhibitory effect of norgesti-
mate on recombinant TRPC6 we next asked whether the
compound similarly affects native TRPC6-mediated currents. In
the aortic smooth muscle cell line A7r5 TRPC6 and/or TRPC6/7
channel complexes had previously been demonstrated to underlie
vasopressin V1a-receptor-activated cation currents [23–25].
Hence, we chose this model and measured inhibition of AVP-
induced receptor-operated currents by norgestimate (Figure 4A).
When 10 mM norgestimate was applied to AVP-stimulated A7r5
cells, receptor-operated cation currents measured at 270 mV
were reversibly reduced by 86.566.0% (n=8), in good agreement
with the effect on recombinant TRPC6 channels. Since AVP-
induced Ca
2+ release was not sensitive to norgestimate
(Figure 4B), receptor-operated channel inhibition is likely due
to a direct effect on the channels proteins rather than interaction of
the compound with upstream signaling elements.
We extended the study of functional effects of norgestimate to
intact vessel segments derived from thoracic rat aorta. Several
investigators have reported expression of TRPC3/6 in this
preparation [5,26]. Isometric force measurement showed that
norgestimate concentration-dependently relaxed aortic segments
Figure 3. Effect of norgestimate on TRPC5-mediated currents. Whole-cell currents evoked by AlF4
2 infusion into TRPC5 expressing HEK-FITR
cells were measured before and after application of 10 mM norgestimate (NG) (A). Current-voltage (I–V) relationships (left panels) and time course of
currents recorded at 270 mV (right panels) are shown. For measurement of I–V curves voltage ramps from 2100 to +80 mV were applied at the time
points indicated. Background currents were isolated by blocking of TRPC5 with 10 mM 2-aminoethoxydiphenyl borate (2-APB). Concentration-
response relationship of the inhibition of TRPC5 by norgestimate (B). Means 6 SEM of n$3 experiments per concentration are shown. The line
represents the best fit of the data to the dose-response equation with a Hill slope of 1.43.
doi:10.1371/journal.pone.0035393.g003
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(Figure 5). To exclude the possibility that norgestimate-induced
relaxation was due to direct receptor blockage we tested the effect
of the compound on recombinant a1-receptors expressed in CHO
cells. Surprisingly, we observed that norgestimate significantly
stimulated phenylephrine-induced Ca
2+ release in this model
(Figure S1). This stimulatory action on a1-receptor signaling may
contribute to the relatively low vasorelaxing activity of norgesti-
mate in isolated aortic rings. Nonetheless, our results indicate that
norgestimate can be used to modulate TRPC-dependent functions
in situ.
Recent experiments revealed that TRPC5 is inhibited by
certain steroids including progesterone in a stereo-selective
manner [19]. Because progesterone is known to induce vasore-
laxation of diverse vessels, we wondered if part of this nongenomic
progesterone effect may be due to inhibition of vascular TRPC
channels. Therefore, we investigated the effects of progesterone on
recombinant TRPC3, 24, 25 and 26. Figure 6 illustrates that
progesterone indeed attenuated Ca
2+ entry through all TRPCs
tested. 12.4 mM and 18 mM progesterone were required for half
maximal inhibition of OAG- induced [Ca
2+]i transients in
TRPC3- and TRPC6 expressing cells. The hormone also
suppressed trypsin-induced Ca
2+ entry via TRPC4 and 25 with
IC50s of 6.2 and 11.8 mM, respectively, demonstrating that
diacylglycerol-insensitive TRPC family members were at least as
sensitive to progesterone treatment as TRPC3 and 26.
These experiments confirm TRPC channels as novel targets of
steroids and raise the possibility that TRPCs contribute to the
vasoregulatory properties of these substances.
Discussion
Our search for new pharmacological TRPC channel modula-
tors led to the discovery of two steroids, namely norgestimate and
progesterone, which differentially inhibited TRPC-mediated
currents and Ca
2+ influx.
Figure 4. Norgestimate blocks AVP-activated non-selective cation currents in A7r5 cells independent of vasopressin receptor
function. Effect of 10 mM norgestimate (NG) on whole-cell currents evoked by 100 nM AVP in A7r5 cells (A). I–V relationships recorded at the
indicated times (left panels) and time course of currents recorded at 260 mV (right panels) are shown. The I–V curves were obtained during voltage
ramps from 2100 to +80 mV. Voltage-gated L-type Ca
2+ channels were blocked by 5 mM nimodipine during the whole experiment. Time-dependent
changes of [Ca
2+]i in fura-2-loaded A7r5 cells (B). Cells were pre-incubated with or without (control) 10 mM norgestimate (NG) in calcium-free (1 mM
EGTA) standard extracellular solution for 5 min before vasopressin receptor stimulation by application of 100 nM AVP. Data represent means 6 SEM
from 33 cells (control) and 36 cells (norgestimate).
doi:10.1371/journal.pone.0035393.g004
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cerol-sensitive TRPC channels. The compound blocked TRPC6
in patch-clamp experiments with an IC50 of ,3 mM and showed a
similar or slightly higher inhibitory potency on TRPC3 currents
and TRPC3-mediated Ca
2+ entry, respectively. Diacylglycerol-
insensitive TRPC5 currents were also reduced by norgestimate but
required a considerably higher concentration (,14 mM) for half
maximal inhibition.
The effects of norgestimate on TRPC currents occurred rapidly,
suggesting a direct modulation of channel proteins rather than
genomic effects via steroid receptors. We could not discern a
significant interference of 10 mM norgestimate with cytosolic
calcium responses elicited by vasopressin receptors in A7r5 cells.
However, the compound up-regulated a1-receptor induced Ca
2+
release in CHO cells. Thus, further evaluation of norgestimate
specificity is needed to fully estimate the potential applications and
limitations of the compound as a blocker of diacylglycerol-sensitive
TRPC channels. Nevertheless, the rather stimulatory effects of
norgestimate on intracellular Ca
2+ release exclude inositol 1,4,5-
trisphosphate receptor antagonism or inhibition of the Gq/11/
phospholipase C signaling cascade as mechanisms of TRPC
channel inhibition.
Figure 5. Endothelium-independent relaxation of pre-contracted rat aortic rings by norgestimate. Representative wire myograph
recording (A) illustrating the effect of norgestimate on L-NAME treated intact aortic rings pre-contracted with phenylephrine. Compounds were
applied as indicated in the perfusate. Acetylcholine (Ach) was applied to demonstrate the absence of endothelium-dependent vasorelaxation. Higher
norgestimate concentrations could not be tested due to the limited solubility of the compound. Concentration-response curve of norgestimate-
induced vasorelaxation (B). Norgestimate-induced relaxation was expressed as percentage of the phenylephrine-induced tension prior to
norgestimate application. The solid line represents the best fit of the data to the Hill model with: y0=24.26%, y1=84.8%, and n=0.93. Data represent
means 6 SEM (n=6).
doi:10.1371/journal.pone.0035393.g005
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2+ influx. Time-dependent changes of [Ca
2+]i in fluo-4-loaded TRPC3 CHO cells (A), TRPC4-
(C), TRPC5- (E) and TRPC6 HEK-FITR (G) cells were measured using a fluorometric imaging plate reader. Representative traces illustrate fluorescence
changes induced by application of 200 nM trypsin or 30 mM OAG with or without pre-incubation with 30 mM progesterone (PG). TRPC-independent
Ca
2+ release in C and E was determined in non-induced TRPC4 and 25 HEK-FITR cells. Concentration response curves for inhibition of TRPC3 (B),
TRPC4 (D), TRPC5 (F) and TRPC6 (H) by progesterone were derived from the area under the fluorescence curves for each given concentration. The
solid lines represent the best fit of the data to the Hill model with slopes of n=3.6 (TRPC3), 1.15 (TRPC4), 2.5 (TRPC5), and 1.2 (TRPC6). Data represent
means of 3 wells (B) or 4 wells (D, F, H). The chemical structure of progesterone is illustrated in B.
doi:10.1371/journal.pone.0035393.g006
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and endogenous vasopressin receptor-activated cation currents in
A7R5 cells with almost the same potency. There is evidence
suggesting that the AVP-induced cation current in A7R5 is carried
by TRPC6/7 heteromeric channels [25]. Based on this assump-
tion it seems plausible, that other possible heteromers formed by
diacylglycerol-sensitive TRPC proteins share a similar high
sensitivity to norgestimate. Therefore, the steroid will be a useful
tool for characterisation of native TRPC3/6/7 containing channel
complexes. In line with this view, our experiments on isolated rat
aorta indicate that norgestimate can be used to investigate TRPC-
mediated functions in tissue preparations.
Norgestimate is a progestin (a synthetic gestagen). Combined
with ethinyl estradiol it is a component of oral contraceptives
widely used in humans. It would be of great interest to investigate
whether other synthetic gestagens share the TRPC-blocking
activity of norgestimate and whether any of the numerous
cardiovascular effects of norgestimate- or other progestin-contain-
ing oral contraceptives can be assigned to TRP channel inhibition.
Prior to this study, Maheed et al. [19] showed that TRPC5 is
inhibited by the pregnancy-maintaining hormone progesterone
and other neurosteroids. Our Ca
2+ measurements extent these
findings and demonstrate that in addition to TRPC5 progesterone
also inhibited TRPC3, 24, and 26. However, in contrast to
norgestimate no preferential effects of progesterone on diacylgly-
cerol-sensitive channel subtypes were observed. This differential
sensitivity of TRPC family members to progesterone and
norgestimate provides further support to the notion that
channel-steroid interaction is based on direct, structure-driven
binding and not caused by unspecific steroid-induced perturbation
of membrane lipid bilayers.
The physiological significance of TRPC channel regulation by
progesterone remains to be established. Our data suggest that in
addition to neurological effects of neurosteroids [19] TRPCs may
contribute to vascular effects of steroid hormones. Several studies
have shown that progesterone rapidly relaxed vessels, e.g. pig
coronary arteries [27] and rat aorta [28,29]. This vasorelaxation is
endothelium-independent and mediated at least partly through
inhibition of L-type Ca
2+ channels [30,31]. Nevertheless, an
involvement of other ion channels, including receptor-operated
cation channels, has also been proposed [28,29] and would be
compatible with the widespread expression of TRPC channels in
smooth muscle (reviewed in [32,33]).
It is of note, that several TRPC channel proteins, in particular
TRPC1, 24, and 26 have been detected in human myometrium
[34–36]. Pregnancy is characterized by elevated progesterone
plasma levels that can reach up to 1 mM [31,37]. Given that
progesterone is highly lipophilic and has a large volume of
distribution [38], tissue concentrations are likely even higher and
may achieve the effective concentrations for TRPC channel
inhibition. Therefore, it is conceivable that TRPC channel
blockade by high gestational progesterone concentrations is part
of the adaptive process that limits uterine contractility during
pregnancy [39].
With estimated 15 mM [40], progesterone concentrations within
the placenta are even higher than in other tissues. Such levels of
progesterone have demonstrated immuno-suppressive effects
important for prevention of fetal-maternal rejection in utero [41].
As many ion channels including TRPCs are involved in
immunomodulation [42] attenuation of TRPC-dependent Ca
2+
signaling could play a role in progesterone-induced immunosup-
pression.
To further corroborate these hypotheses studies of TRPC
channel regulation by steroid hormones in native tissues are highly
desirable.
Supporting Information
Figure S1 Stimulatory effect of norgestimate on a1A-
receptor-mediated Ca
2+ signaling in CHO cells. (A)
Phenylephrine (Phe) -induced changes of [Ca
2+]i were measured
in a stable CHO cell line expressing human a1A-adrenoceptors.
Cells loaded with fluo-4 were pre-incubated with or without
30 mM norgestimate (NG) and challenged with 10 mM phenyl-
ephrine or control buffer. Representative traces are shown.
Fluorometric imaging plate reader [Ca
2+]i measurements were
performed essentially as described for HEK-FITR cells (see
Materials and Methods) with the exception that the extracellular
buffer contained 1 mM EGTA instead of 2 mM Ca
2+.( B) The
relative increase in Ca
2+ release induced in the presence of
different concentrations of norgestimate is shown. Release was
estimated from the area under the curve after application of
phenylephrine and normalized to the effect in the absence of
norgestimate. Data shown represent means 6 SEM (n=4).
Significance of changes vs. control is indicated by *(p,0.05), **
(p,0.01), and *** (p,0.001).
(TIF)
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